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Background: Lymphangiogenesis is one of the major causes of corneal graft rejection. Among the
lymphangiogenic factors, vascular endothelial growth factor (VEGF)-C and -D are considered to be the most potent.
Both bind to VEGF receptor 3 (VEGFR3) to activate Prospero homeobox 1 (Prox1), a transcription factor essential for
the development and maintenance of lymphatic vasculature. MicroRNAs (miRNAs) bind to the 3' untranslated
regions (3' UTRs) of target genes in a sequence-specific manner and suppress gene expression. In the current study,
we searched for miRNAs that target the pro-lymphangiogenic factor Prox1.
Results: Among the miRNAs predicted by the bioinformatic analysis to seed match with the 3' UTR of Prox-1, we
chose 3 (miR-466, miR-4305, and miR-4795-5p) for further investigation. Both the miR-466 and miR-4305 mimics, but
not the miR-4795-5p mimic, significantly reduced the luciferase activity of the Prox-1 3' UTR reporter vector. In
primary lymphatic endothelial cells (HDLEC), miR-466 mimic transfection suppressed Prox1 mRNA and protein
expression, while miR-4305 mimic transfection did not. Experiments using mutated reporter constructs of the two
possible seed match sites on the 3' UTR of Prox1 suggested that the target site 2 directly bound miR-466. HDLEC
transfected with the miR-466 mimic suppressed tube formation as compared to the scrambled control. Furthermore,
HDLEC transfected with a miR-466 inhibitor showed enhanced tube formation as compared to control inhibitor
transfected cells, and this inhibitory effect was counteracted by Prox1 siRNA. The miR-466 mimic reduced angiogenesis
and lymphangiogenesis resulting in clearer corneas in an cornea injury rat model compared to the scrambled control.
Conclusions: Our data suggest that miR-446 may have a protective effect on transplanted corneas by suppressing
Prox1 expression at the post-transcriptional level. The results of the current study may provide insights into the
mechanisms of lymphangiogenesis resulting from corneal graft rejection and alkali-burn injuries, as well as into the
development of new treatments for lymphangiogenic eye diseases.
Keywords: MicroRNA, Prox1, miR-466, miR-181, Tube Formation, Lymphangiogenesis, Cornea transplantation, Alkali
burnBackground
Approximately 10%–50% of cornea transplantation recipi-
ents experience graft rejection within one year [1]. Cor-
neal graft rejection takes place when the immune cells of
the host recognize the donor tissues as antigens and attack
them. The normal cornea maintains avascularity by balan-
cing positive and negative angiogenesis-regulating mole-
cules such as vascular endothelial growth factor (VEGF)* Correspondence: sukklee@catholic.ac.kr
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unless otherwise stated.and angiostatin, respectively. Stimulation of cornea caused
by corneal transplantation promotes the production of
VEGF, disrupts the balance, and results in capillary endo-
thelial cell proliferation and neovascularization [2,3]. Cor-
neal lymphangiogenesis is also induced after corneal
transplantation [4]. While the blood vessels provide a
route of entry for CD4+ alloreactive T lymphocytes and
memory T lymphocytes [5], newly formed corneal lymph-
atic vessels enable effective access of antigen presenting
cells and antigenic materials to lymph nodes where accel-
erated sensitization to graft antigens occurs [6].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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vessels from existing blood vessels, is promoted by pro-
angiogenic factors, such as VEGF, angiopoietins, and
integrins [7]. The potent angiogenic inducer VEGF-A can
bind to both VEGF receptor 1 (VEGFR1) and VEGFR2.
However, the signals responsible for inducing prolifera-
tion and migration of vascular endothelial cells are
mainly transduced via VEGFR2 [8].
Lymphangiogenesis is known to be closely associated
with inflammation, wound healing, corneal graft rejection,
and tumors. The cell survival, proliferation, and migration
of epithelial cells are important process in lymphangiogen-
esis, which depends on VEGF-C and -D signalling path-
ways through VEGFR-2 and VEGFR-3 [9,10]. Especially,
VEGF-C and –D bind with VEGFR-3 and activate Pros-
pero homeobox 1 (Prox1) [11]. Prox1 is homolog of the
drosophila homeobox protein prospero [12]. Prox1 is a
transcription factor essential for the embryonic develop-
ment of vertebrates, and the development and mainten-
ance of lymphatic vasculature in adulthood [13-15].
Following transplantation of corneas from C57BL/6
mice into BALB/C mice, the graft survival rates were
compared between two experimental groups [16]. In one
group, VEGF-TrapR1R2 was used to inhibit both lym-
phangiogenesis and angiogenesis, and in the other,
VEGFR3 Ab mF4-31C was used to inhibit lymphangio-
genesis only. Results showed that the survival rates of the
corneal grafts were comparable in the two groups, indi-
cating that lymphangiogenesis but not angiogenesis was
an important determinant for graft survival rates.
Inflammation-induced lymphangiogenesis has been re-
ported to be attributable to the increased expression of
Prox1 stimulated by inflammatory responses [17]. In par-
ticular, Prox1 promotes the expression of the VEGF-C
receptor, VEGFR3 [18]. In Prox1+/− mice, milky chyle
leaked from the mesenteric lymphatic vessels, and
abnormal lymphatic ducts were formed [19]. Further-
more, embryos of Prox1-knockout mice showed a loss of
lymphangiogenesis without disrupted hemangiogenesis
from the cardinal vein [13]. Therefore, inhibiting Prox1
function or reducing Prox1 expression may be effective
strategies for inhibiting corneal lymphangiogenesis.
MicroRNAs (miRNAs) are highly conserved small non-
coding RNAs (19–25 nucleotides) that can modulate
gene expression. Primary miRNA transcripts are proc-
essed consecutively to produce mature miRNAs by the
two RNase III endonucleases, Drosha and Dicer. Mature
miRNAs function as negative gene regulators through
complementary sequence pairing with the 3' untranslated
regions (3' UTRs) of target genes [20].
Kazenwadel et al. [21] reported that the over-expression
of miR-181a in mouse lymphatic endothelial cells directly
targeted the 3' UTR of Prox1, and the expression of miR-
181a was lower in vascular endothelial cells than inlymphatic endothelial cells. Furthermore, the expression
of miR-181a was inversely related to the expression of
Prox1 [21]. Other investigators found that miR-31 targets
the 3' UTR of Prox1 to suppress its expression in human
lymphatic endothelial cells, and that over-expressed miR-
31 led to defective lymphangiogenesis in Xenopus and
zebrafish embryos [22]. However, there may be other un-
known miRNAs capable of down-regulating Prox1 ex-
pression as well.
In the current study, miR-466, miR-4305, and miR-
4795-5p were chosen as new miRNA candidates that
could target the 3' UTR of Prox1 based on the results of
a bioinformatics analysis. The ability of these miRNAs to
suppress the expression of Prox1 in vitro was then inves-
tigated. The in vivo inhibitory effects of these miRNAs
on lymphangiogenesis were also assessed using an ex-
perimental alkali corneal burn animal model.
Methods
Cells
Human dermal lymphatic endothelial cells (HDLEC)
were purchased from PromoCell (Heidelberg, Germany)
and cultured in MV2 media (PromoCell). HEK293T were
cultured in DMEM (Gibco BRL, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum and antibi-
otics (100 U/mL penicillin and 100 μg/mL streptomycin;
Gibco BRL). Both cells were incubated at 37°C and sup-
plemented with 5% CO2.
miRNA mimics, siRNA, and miRNA inhibitor
The miRNA mimics, siRNA, and scrambled miRNA used
as a negative control were purchased from Genolution
Pharmaceuticals (Seoul, South Korea). The sequences are
as follows: scrambled control sense, 5′-UUUUAACUCA
GUAUUUUUA-3′ and antisense, 5′-UAAAAAUACUGA
GUUAAAA-3′; Prox1 siRNA sense, 5′- GAGUUGACA
UUGGAGUGAA-3′ and antisense, 5′- UUCACUCC A
AUGUCAACUC-3′. The LNA™ microRNA Power In-
hibitor for hsa-miR-466 and the negative control inhibitor
(NC inhibitor) were purchased from Exiqon (Vedbaek,
Denmark). The sequences are as follows: inhibitor for
hsa-miR-466, 5′-GTGTTGCGTGTATGTGTA-3′; NC
inhibitor, 5′-GTGTAACACGTCTATACGCCCA-3′.
Plasmid construction and site-directed mutagenesis
The full length 3' UTR of Prox1 was amplified from the
genomic DNA of HEK293T cells and cloned between the
Renilla luciferase coding sequence and the poly(A) site of
the psiCHECK-2 plasmid (Promega, Madison, WI, USA)
using XhoI/NotI sites to produce psiC-Prox1. The primers
used for the amplification of 3′ UTR of Prox1 were as fol-
lows: 5′-TCGACTCGAGTGCCTACAAGAGCTGCTTC
A-3′ and 5′-GGCCGCGGCCGCATTTGGCCTTTTGG
GGTACT-3′. Mutations were introduced into the putative
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To test whether the miRNAs directly target the 3' UTR
of Prox1, luciferase reporter assay was carried out. For
this, HEK293T cells were seeded in a 96-well plate (5 ×
103 cells/well). After 24 h, cells were co-transfected with
20 ng psiC-Prox1 or its mutants (psiC-Prox1-m1, psiC-
Prox1-m2, and psiC-Prox1-m1m2), and 10 nM each of
the miRNA mimics. Luciferase activities were measured
48 h post-transfection using the Dual-Glo™ luciferase re-
porter assay system (Promega). Renilla luciferase activity
was normalized using firefly luciferase activity for each
sample.
Transfection of HDLEC
Cells were seeded 24 h prior to transfection in 60- or
100-mm-diameter dishes containing 10 mL culture
medium. Transfection was performed with 20 nM each
of miRNA mimic, siRNA, and/or miRNA inhibitor using
Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer's protocol. Cells were har-
vested for RNA and protein extraction 48 h after
transfection.
Quantitative reverse transcription-polymerase chain reac-
tion (qRT-PCR)
HDLEC were harvested and total RNA was extracted
using the RNAzol™ B reagent (Tel-Test, Friendswood,
TX, USA) according to the manufacturer's instruction.
cDNA was synthesized using 1 μg total RNA, oligo(dT)
(Macrogen, Seoul, South Korea), and M-MLV reverse
transcriptase (Invitrogen). Real-time PCR for Prox1 was
carried out using a SYBR green qPCR kit (Takara, Tokyo,
Japan) with an Mx3000P™ Real-Time PCR System
(Stratagene, La Jolla, CA, USA). The sequences of the
primers were as follows: Prox1; 5′-ATCCCAGCTCCAA-
TATGCTG-3′ and 5′-GTACTGGTGACCCCATCGTT-
3′, glyceraldehyde phosphate dehydrogenase (GAPDH);
5′- ATGGGGAAGGTGAAGGTCG-3′ and 5′- GGGG
TCATTGATGGCAACAATA-3′. The PCR conditions
were 95°C for 10 min, followed by 40 cycles at 95°C for
20 s, 60°C for 30 s, and 72°C for 30 s. To confirm specific
amplification of the PCR product, dissociation curves
were checked routinely. For this, the PCR products were
incubated at 95°C for 10 s and ramped up from 55°C to
95°C with a heating rate of 0.1°C/s, and fluorescence was
measured continuously. Relative gene expression wascalculated according to the comparative Ct method using
GAPDH as an internal standard.
Western blot analysis
To detect the Prox1 protein, cell lysate in RIPA buffer
(50 μg) was mixed with NuPAGE LDS sample buffer
(4×) and heated at 70°C for 10 min. The samples were
electrophoretically separated on 8% SDS-PAGE gel, and
then transferred to a nitrocellulose membrane (Invitro-
gen). The membrane was incubated overnight at 4°C
with mouse monoclonal antibody against Prox1 (1:500,
Abnova, Taipei City, Taiwan). After washing, the blots
were incubated for 2 h at room temperature with horse-
radish peroxidase-conjugated anti-mouse secondary
antibody (1:5000, Santa Cruz Biotechnology, Dallas, TX,
USA). Protein bands were visualized using an enhanced
chemiluminescence detection system (Amersham Bio-
sciences). β-Actin antibody (Cell Signaling Technology,
Danvers, MA, USA) was used to confirm comparable
loading. The density of each protein band was read and
quantified using Fujifilm Multi Gauge software (version
3.0).
Tube formation assay
Endothelial cells plated on a reconstituted basement
membrane matrix have been known to rapidly attach,
align, and form capillary-like tubules [23]. As this endo-
thelial cell specific process is rapid and quantifiable, tube
formation assay has been used to study angiogenic and
anti-angiogenic factors, to investigate mechanisms of
angiogenesis, and to define endothelial cell populations
[23]. To assess the effect of miRNAs on lymphangiogen-
esis of HDLEC, tube formation experiments were per-
formed using MILLIPORE® In Vitro Angiogenesis Assay
Kit (MILLIPORE, Billerica, MA, USA) according to the
manufacturer's protocol. Ninety six-well plates were coated
with cold liquid ECMatrix (70 μl/well) and incubated at
37°C in a humidified 5% CO2 incubator for 1 h to promote
solidification. miRNA-transfected cells (7 × 103cells/well)
were seeded into 96-well plates pre-coated with polymer-
ized ECMatrix and incubated with conditioned media at
37°C for 4–6 h. Formation of tube-like structures was ob-
served under a phase-contrast microscope and quantified
by counting the number of tubes formed in 3 randomly
chosen fields using ImageJ software.
Experimental corneal alkali burn animal model
Male Sprague–Dawley rats (body weight, approximately
250–300 g) were used in this study. All of the animals
were treated in accordance with the guidelines of the As-
sociation for Research in Vision and Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmic
and Vision Research, and the study protocol was ap-
proved by the Committee for Animal Research, Catholic
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via intraperitoneal injection of 50 mg/kg tiletamine plus
zolazepam (Zoletil; Virbac, Carros, France) and 15 mg/kg
xylazine hydrochloride (Rompun; Bayer, Leuverkeusen,
Germany). Alkali injuries to the eyes were induced via 10 s
exposure of the central cornea to a 4-mm-diameter disk of
filter paper soaked in 1 N NaOH, followed by rinsing with
sterile saline (10 mL). To avoid any corneal infection, one
drop of antibiotic (0.5% levofloxacin; Cravit; Santen,
Osaka, Japan) was instilled onto the ocular surface imme-
diately after the alkali burn injury. The animals were then
randomly allocated to three treatment groups: scrambled
control, miR-181a, and miR-466. Each group (n = 10) was
treated with a single subconjunctival injection with 20 μl
of 20 nM miRNA mimic immediately after the alkali burn
injury.
Immunostaining
Formalin-fixed corneas from each group of animal were
embedded in paraffin and 4 μm sections were prepared
for examination. To access lymphangiogenesis, corneal
sections were stained with and anti-mouse lymphatic
vessel endothelial hyaluronan receptor (LYVE)-1 anti-
body (1:500; Abcam, Eugene, OR, USA) for 16 h at 4°C.
After three washes with PBS for 15 min, the sections
were then stained with a Texas Red-conjugated second-
ary antibody (Abcam). To detect F-actin, corneal sections
were incubated with rhodamine-conjugated phalloidin
(dilution 1:500, Abcam) for 1 h and washed three times
with PBS. The stained sections were incubated with
hoechst solution to stain nucleus before examined by
fluorescence microscopy at 100× magnification.
Results
Screening of miRNAs that can target Prox1
In order to screen miRNAs which may target Prox1, we
used publicly available TargetScan program (http://www.
targetscan.org) and found 17 human microRNAs that
showed a good seed match with the 3' UTR of human
Prox1 mRNA (Additional file 1: Table S1). Among the
17 miRNAs, we selected miR-4305 and miR-4795-5p for
further study, as they both showed 8mer seed matches
with the 3' UTR of human Prox1(Figure 1A). This was
considered to be important due to similarity with miR-
181a, which was previously shown to target Prox1. Add-
itionally, miR-466 was also selected, as the 3' UTR of
Prox1 contained two putative binding sites for this
miRNA (7mer-m8 and 7mer-1A sites), unlike other miR-
NAs. Although miR-4262 showed an 8mer seed match
with the 3' UTR of Prox1, it was excluded from further
study because the 8mer seed sequence of miR-4262 was
identical to that of miR-181a. As the target sequences of
miRNAs are frequently conserved in many species, we
analyzed conservation of the seed match sequences inthe 3' UTR of Prox1. The 7mer-1A site complementary
to the target site 2 of miR-466 and the 8mer site com-
plementary to the seed region of miR-4305 were well
conserved among species (Figure 1B). However, the
7mer-m8 site complementary to the target site 1 of miR-
466 and the 8mer site complementary to the seed region
of miR-4795-5p were not well conserved. Subsequently,
a luciferase reporter assay was conducted to assess
whether miR-466, miR-4305, and miR-4795-5p directly
targeted the 3' UTR of Prox1. First, HEK293T cells were
co-transfected with psiC-Prox1 and each miRNA mimic.
miR-181a, which is known to target Prox1, was included
as a positive control, while a scrambled miRNA was
used as a negative control. As expected, miR-181a sig-
nificantly reduced the luciferase activity of psiC-Prox1 as
compared to the scrambled control. The miR-466 and
miR-4305 mimics, but not the miR-4795-5p mimic, sig-
nificantly reduced the luciferase activity of the reporter
vector as compared to that of the scrambled control
(Figure 1C).Effect of miRNA mimics on the expression of Prox1 mRNA
and protein
To test whether miR-466 and miR-4305 have the ability
to modulate Prox1 expression, HDLEC were harvested
48 h after miRNA mimic transfection. qRT-PCR revealed
that the Prox1 mRNA level was reduced by approxi-
mately 50% following transfection with the miR-181a
mimic. Similarly, the Prox1 mRNA level was decreased
by about 50% following transfection with the miR-466
mimic as compared with the scrambled control (Figure 2A).
miR-4305 transfection did not affect Prox1 mRNA level
significantly. Western blot analysis also showed that the
level of Prox1 protein was reduced by transfection with the
miR-181a and miR-466 mimics as compared to levels ob-
served following transfection with the scrambled control
(Figure 2B). However, the level of Prox1 protein was not
significantly affected by miR-4305.Dose-dependent effect of the miR-466 mimic
As non-specific effects can obscure the results of
miRNA mimic transfection experiments, we carried out
a luciferase assay using increasing doses of the miR-466
mimic. To accomplish this, HEK293T cells were co-
transfected with increasing concentrations of the miR-466
mimic and psiC-Prox1 reporter plasmid. Transfection
with 5 nM miR-466 slightly reduced the luciferase
activity, however the reduction was not statistically sig-
nificant as compared to the scrambled control transfec-
tion (Figure 3). Transfecting the cells with 10 nM or
higher concentrations of the miR-466 mimic caused a
dose-dependent reduction in the luciferase activity of
psiC-Prox1 (Figure 3). To minimize any possible non-
Figure 1 Search for miRNAs targeting Prox1. (A) Seed matches between the 3' UTR of Prox1 and miR-466, miR-4305, and miR-4795-5p. The
coordinates for miR-466 target sites 1 and 2, as well as the target site for miR-4305 and miR-4795-5p, are shown in parentheses (GenBank
accession number NM_002763). (B) Cross-species sequence alignment of the 3' UTR of Prox1. The shaded boxes are putative miR-466, miR-4305,
and miR-4795-5p target sites. Con indicates conserved residues. Alignment of the Prox1 3' UTR shows the sequence conservation among the
human (has), chimpanzee (ptr), mouse (mmu), rat (rno), rabbit (ocu), and dog (cfa). Numbers indicate the nucleotide position after the stop codon
of Prox1. (C) Direct targeting of the Prox1 3' UTR by miR-466, miR-4305, and miR-4795-5p. Luciferase activity was measured in HEK293T cells
co-transfected with psiC-Prox1 and the miR-466, miR-4305, or miR-4795-5p mimics. miR-181a, which was reported to target Prox1, was used as a
positive control. Luciferase activity was normalized using internal firefly luciferase activity, and expressed as a ratio to the luciferase activity
obtained from the scrambled control-transfected cells. Error bars indicate SDs (n = 3 per experiment). *P < 0.05. †P < 0.01.
Seo et al. Journal of Biomedical Science  (2015) 22:3 Page 5 of 12specific effects, we used 10–20 nM miRNA mimics
throughout the experiments.
Confirming target sites for miR-466 in the Prox1 3' UTRs
The 3' UTR of Prox1 contains two putative binding sites
for miR-466 (Figure 1A). To test whether both were
directly targeted by miR-466, point mutations were intro-
duced to psiC-Prox1 to produce psiC-Prox1-m1, psiC-
Prox1-m2, and psiC-Prox1-m1m2 (Figure 4A and B).
Each of these vectors was co-transfected with the miR-
466 mimic into HEK293T cells, and the luciferase assaywas conducted. Luciferase activity was partially reduced in
the cells transfected with the miR-466 mimic together
with either psiC-Prox1 or psiC-Prox1-m1 (Figure 4C).
However, luciferase activity was unaffected in the cells
transfected with the miR-466 mimic together with psiC-
Prox1-m2 (Figure 4C). As expected from the fact that
both of the putative seed match sites were eliminated,
luciferase activity was not affected when psiC-Prox1-
m1m2 was co-transfected with miR-466 (Figure 4C).
Luciferase activity was not affected in the cells co-
transfected with wild-type or mutant Prox1 3' UTR
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466) or the scrambled control (Figure 4C). These re-
sults showed that target site 2, but not the target site 1,
on the 3' UTR of the Prox1 was targeted by miR-466.
Effect of miRNAs on tube formation in HDLEC
To test whether miR-466 has an anti-lymphangiogenesis
effect, an in vitro tube formation assay was conducted.
Forty eight hours after transfection with miR-466 mimic,
HDLEC were cultured on a Matrigel-coated 96 well plate
for 4–6 h and the extent of tube formation was assessed.
Formation of a rich network of tubular structures was ob-
served in HDLEC transfected with the scrambled miRNA.
miR-466 mimic significantly impaired the tube-forming ac-
tivity of HDLEC as compared to the scrambled control
(Figure 5A). Tube formation was then quantified by meas-
uring the number of tubes formed using image manipula-
tion software (ImageJ). The miR-181a mimic exerted the
highest level of inhibitory effects on tube formation (ap-
proximately 84%) followed by the miR-466 mimic (ap-
proximately 57%; Figure 5B) when compared to the
scrambled control. We also tested whether the inhibition
of miR-466 enhanced tube formation in HDLEC and
whether Prox1 siRNA counteracted the effect of a miR-466
inhibitor. As expected, Prox1 siRNA transfection signifi-
cantly decreased Prox1 expression in HDLEC as compared
to transfection with the scrambled control (Figure 5C).
HDLEC were then transfected with a miR-466 inhibitor
alone or together with Prox1 siRNA. HDLEC transfected
with the miR-466 inhibitor alone showed significantly in-
creased tube formation (Figure 5D and E). However, co-
transfected Prox1 siRNA counteracted the effect of the
miR-466 inhibitor (Figure 5D and E).
Effect of miRNAs on angiogenesis and lymphangiogenesis
in the corneal alkali burn animal model
The effects of miRNAs on corneal opacity, angiogenesis,
and lymphangiogenesis were examined in an experimental
animal model. Immediately after inducing an alkali burn,
each miRNA mimic was subconjunctivally injected once,
and the effect of each miRNA was evaluated two weeks
later. miR-181a was used as a positive control, while the
scrambled miRNA was used as a negative control. In the
scrambled control-injected animals, the injured central
corneal stroma appeared opaque with a distinct edematous
margin (Figure 6A). In contrast, miR-466- or miR-181a-
injected animals showed reduced opacity (Figure 6B and
6C). Under direct microscopic observation, blood vascular
infiltration was about 46% of the scrambled control group
level in the miR-181a-treated group. When the animals
were injected with miR-466, blood vascular infiltration was
51% of the scrambled control group level (Figure 6J). Infil-
tration of blood vessel into the cornea was examined by
staining with phalloidin to detect F-actin (Figure 6D-F),and positive cells were quantified using the ImageJ soft-
ware. The cornea section from the scrambled miRNA-
injected eyes showed a thickened cornea and strong scat-
tered F-actin staining. In the miR-181a-treated group, the
cornea showed almost half the thickness and F-actin posi-
tive staining was about 38% compared to the scrambled
control group (Figure 6K). When the animals were injected
with miR-466, corneal thickness was between those ob-
served for the scrambled control and the miR-181a-
injected animals, while F-actin positive staining was 56% of
the scrambled control group level (Figure 6K). To analyze
the effects of miRNAs on lymphangiogenesis of the cornea,
corneal sections from each animal group were analyzed by
immunohistofluorescence staining with anti-LYVE-1 anti-
bodies (Figure 6G-I). miR-466- and miR-181a-injected cor-
neas showed significantly reduced levels of LYVE-1
staining (~33% and ~30%, respectively) compared to the
scrambled control-treated corneas (Figure 6L).
Discussion
The results of the current study showed that the expres-
sion of Prox1 was inhibited by miR-466 at both the
mRNA and protein levels. The luciferase assay showed
that miR-466 directly targeted the well conserved 7mer-
1A site in the 3' UTR of Prox1 (target site 2), as the
suppressive effect of the miR-466 mimic on luciferase ac-
tivity was almost abolished when this site was mutated.
The target site 2, unlike the target site 1, was well con-
served among species. Previous reports showed that add-
itional Watson-Crick pairing to four or five sequential
nucleotides at nucleotides 12–17 enhanced miRNA tar-
geting [24]. The target site 2 contains five contiguous se-
quences that can be used for an effective 3' pairing with
the nucleotides 14 ~ 18 of miR-466, while the target site
1 does not. Thus, the target site 2 seems to have better
chance to be targeted with miR-466 than the target site 1.
In the alkali burn corneal injury model, miR-466 de-
creased corneal opacity and inhibited both lymphangiogen-
esis and angiogenesis, possibly attributable to decreased
Prox1 expression. According to the results of a recent
study [25], growth and migration of vascular endothelial
cells were decreased by the addition of culture supernatant
derived from Prox1 siRNA-treated oral squamous cell car-
cinoma cell cultures. In that experiment, down-regulation
of VEGF-C was observed following silencing of the Prox1
gene [25]. These results suggested that Prox1 acted as a
regulator of angiogenesis and lymphangiogenesis in oral
squamous cell carcinoma [25]. Prox1 is known to control
the expression of angiopoietin-2, which promotes angio-
genesis in vascular endothelial cells [26]. VEGF-C and
angiopoietin-2 are also important modulators of angiogen-
esis [27,28]. Therefore, suppressed Prox1 expression by
miR-466 may have inhibited the expression of angiogenic
modulators such as VEGF-C and angiopoietin-2, resulting
Figure 2 Effects of miR-466 and miR-4305 on Prox1 expression. (A) Reduction in Prox1 mRNA levels by miR-466. HDLEC were transfected
with the miR-181a, miR-466, miR-4305 mimics, or the scrambled control. The cells were then cultured for 48 h and harvested for use in real-time
qRT-PCR analyses (n = 3). Error bars indicate SDs. †P < 0.01. (B) Effects of miR-466 and miR-4305 on the expression of Prox1 protein. HDLEC were
transfected with miR-181a, miR-466, miR-4305 mimics, or the scrambled control. The cells were cultured for 48 h and then harvested for analysis.
The band densities obtained using an anti-Prox1 antibody were divided by those obtained using an anti–beta-actin antibody to normalize protein
loading. Western blotting was conducted using three sets of independently transfected HDLEC. Bands were quantified using Fujifilm Multi Gauge
software (version 3.0). Means were calculated using data from all three independent experiments and are expressed as ratios to the value
obtained from the scrambled control-transfected HDLEC. Error bars indicate SDs. *P < 0.05. †P < 0.01.
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animal model. However, as miRNAs usually have multiple
targets, our observations may be attributable to angiogenic
modulators other than Prox1 targeted by miR-466. This
notion is supported by previous findings demonstrating
that miR-466 induced apoptosis by targeting a few anti-Figure 3 Dose-dependent effect of the miR-466 mimic.
Luciferase activity was measured in HEK293T cells co-transfected
with increasing concentrations of the miR-466 mimic and psiC-
Prox1. Error bars indicate SDs (n = 3 per experiment). *P < 0.05.apoptotic genes [29], and that this induced apoptosis re-
sulted in the inhibition of angiogenesis [30,31].
mmu-miR-466, which can be induced by apoptosis [29]
and metabolic oxidative stress [32], was shown to en-
hance viral replication by inhibition of INF-α [33]. In
addition, over-expression of mmu-miR-466 inhibited
Nfat5 expression and was associated with renal dysfunc-
tion [34]. However, the functions of hsa-miR-466 in hu-
man cells have yet to be fully elucidated. The results of
the current study demonstrated that hsa-miR-466 inhib-
ited Prox1 expression and suppressed tube formation in
human primary lymphatic endothelial cells. Furthermore,
miR-466 reduced angiogenesis and lymphangiogenesis,
resulting in clearer corneas than those observed in the
scrambled control-treated mice in an animal cornea in-
jury model.
The inhibitory effects of miR-466 on Prox1 expression,
tube formation, and lymphatic vessel formation were
comparable to those of miR-181. However, the inhibitory
effect of miR-466 on blood vessel formation in the
in vivo corneal injury model was slightly weaker than that
of miR-181a. Findings of discrepant efficiencies attrib-
uted to miRNAs measured using different methods are
not rare [35,36] and may be due to different experimental
settings, or may reflect experimental errors. Another
Figure 4 Target site search for miR-466 in the Prox1 3' UTR. (A) Illustration showing (i) the location of possible seed match sites between
miR-466 and the 3' UTR regions and (ii) the sites altered to produce mutant forms of psiC-Prox1. Site-directed mutagenesis was performed to
produce mutant versions of the 3' UTR of Prox1 seed match sequence (psiC-Prox1-m1, psiC-Prox1-m2, and psiC-Prox1-m1m2). (B) Seed matches
between miR-466 and the mutated 3' UTRs of Prox1. wt, wild type. (C) Luciferase activity was measured in HEK293T cells co-transfected with the
miR-466 mimic and a luciferase reporter vector containing the wild-type or mutated 3' UTRs of Prox1. The scrambled control and miR-466 m
(mutant form) were used to confirm sequence-specific binding between miR-466 and the 3' UTRs. Luciferase activity was normalized using firefly
luciferase activity and expressed as a ratio of the luciferase activity to the activity obtained from the scrambled control-transfected cells. Error bars
indicate SDs (n = 3 per experiment). *P < 0.05. †P < 0.01.
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related genes other than Prox1 more effectively than
miR-466.
miR-4305 also significantly reduced the luciferase activ-
ity of the Prox1 3' UTR reporter vector as compared to
the scrambled control in this study. However, Prox1 ex-
pression was not changed following miR-4305 mimic
transfection of HDLEC compared to the scrambled con-
trol transfection. It is not clear why the miR-4305 mimic
showed discrepant results in the luciferase assay, and in
qRT-PCR and western blot experiments. These discrep-
ant findings may be due to the use of only the 3' UTR ofProx1, as opposed to the whole Prox1 mRNA, in the lu-
ciferase assay. The seed match sequence on the 3' UTR
of Prox1 in the luciferase reporter construct may have
been available for miR-4305 binding, while the confirm-
ation of that sequence in the Prox1 mRNA may have not
allowed for miR-4305 binding. In addition, HEK293T
cells were used for the luciferase assay, while HDLEC
were used for other experiments.
Bevacizumab is a recombinant humanized immuno-
globulin G1 monoclonal antibody against all isoforms of
VEGF-A [37]. Bevacizumab binds VEGF-A and prevents
the interaction of VEGF-A to its receptor on the surface
Figure 5 Effect of miRNAs on tube formation in HDLEC. (A, D) HDLEC were transfected with 20 nM each of the miRNA mimics, miRNA
inhibitor and/or siRNA. After 48 h, the HDLEC cells (7 × 103 cells/well) were plated on ECMatrix-coated tissue culture plates in endothelial culture
medium including 10 ng/mL basic fibroblast growth factor, 5 ng/mL epidermal growth factor, 20 ng/mL insulin like growth factor 1, and 0.5
ng/mL VEGF. Capillary-like structures within the Matrigel layer were photographed after 4–6 h under a microscope (×50). Defective tube formation
points are marked with black arrows. (B) Results similar to those in panel A were obtained in two additional independent experiments, and tube
formation was quantified using the ImageJ software. Means were calculated using data from all three independent experiments and expressed as
ratios to the value obtained from the scrambled control-transfected HDLEC. (C) Effects of Prox1 siRNA on the expression of Prox1 protein. HDLEC
were transfected with 20 nM Prox1 siRNA or the scrambled control. Cells were cultured for 48 h and then harvested for analysis. Western blotting
was conducted using three sets of independently transfected HDLEC. Bands were quantified using Fujifilm Multi Gauge software (version 3.0).
Means were calculated using data from all three independent experiments and are expressed as ratios to the value obtained from the scrambled
control-transfected HDLEC. (E) Results similar to those in panel D were obtained in two additional independent experiments, and tube formation
was quantified using ImageJ software. Means were calculated using data from all three independent experiments and are expressed as ratios to
the value obtained from the scrambled control-transfected HDLEC. Error bars indicate SDs. *P < 0.05. †P < 0.01.
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Figure 6 Inhibition of corneal neovascularization by miRNAs in a corneal injury animal model. Alkali burn-induced corneas of Sprague–
Dawley rats were treated once with each miRNA mimic by subconjunctival injection on the day of injury. (A-C) Photographic images of corneas
treated with each miRNA mimic. Immunofluorescent stain of corneal sections to detect vessel formation (D-F) or lymphangiogenesis (G-I). Red
stains F-actin (D-F) or LYVE-1 (G-I), which is a marker of vessels and lymphatic vessels, and blue shows hoechst staining (D-I). Photographs of
corneas were taken two weeks after the treatment. (J) Quantification of new blood vessel formation, F-actin-stained area (K), and LYVE-1-stained
area (L). Relative rate was quantified using ImageJ software and normalized to the value obtained from the scrambled control-injected rats. Error
bars indicate SDs. †P < 0.01.
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cell proliferation and new blood vessel formation [38].
Since the FDA approved bevacizumab for the treatment
of metastatic colorectal cancer in combination with
5-fluorouracil, bevacizumab has been used for var-
ious malignancies [38,39]. Although bevacizumab-based
treatment on eye diseases has not been approved by the
FDA, intravitreal bevacizumab injection led to improve-
ment of visual acuity and regression of retinal neovascu-
larization in proliferative diabetic retinopathy patients
[40]. Likewise, intraocular pressure and angiogenesisdecreased following the administration of bevacizumab
eye drops in neovascular glaucoma patients [41]. Fur-
thermore, subconjunctival administration of bevacizu-
mab after corneal transplantation decreased the number
and caliber of vessels, however the effects were transi-
ent [42]. Bevacizumab inhibits only VEGF-A-induced
lymphangiogenesis and has no effects on the lymphan-
giogenesis caused by VEGF-C or VEGF-D [43]. To treat
lymphangiogenesis-related disease more effectively, it is
necessary to develop drugs that directly target the
process of lymphangiogenesis.
Seo et al. Journal of Biomedical Science  (2015) 22:3 Page 11 of 12The results of the current study demonstrated that
miR-466 inhibited Prox1, which is known to be activated
by various growth factors including VEGF-A, −C, and -D
[11,44]. Thus, miR-466 is expected to have broader and
greater inhibitory effects on lymphangiogenesis-related
diseases than bevacizumab.
Conclusions
Our results on human lymphatic endothelial cell and al-
kali burn corneal injury model demonstrated that miR-
466 directly targeted the 3' UTR of Prox1 and suppressed
the expression of Prox1, resulting in inhibition of lym-
phangiogenesis. Therefore, miR-466 may be useful for in-
vestigating the mechanisms of lymphangiogenesis and for
developing treatments for lymphangiogenic eye diseases.
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